The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2023 | Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma
Paul Harker-Murray, MD, PhD, Medical College of Wisconsin, Milwaukee, WI, comments on the results of a study that evaluated nivolumab and brentuximab vedotin with or without bendamustine in patients with relapsed/refractory (R/R) Hodgkin Lymphoma (HL) at low risk of relapse. Dr Harker-Murray explains that this regimen was highly efficacious, suggesting that this subgroup of patients can be cured without autologous transplantation. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
